Clinical Trial: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
Study Status: Completed
Recruit Status: Completed
Condition: Primary Immune Thrombocytopenia
Study Type: Interventional
Official Title: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial
Brief Summary:
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with primary chronic ITP.
Read more